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Generalized vitiligo (GV) is a complex disease in which
patchy depigmentation results from autoimmune loss
of melanocytes from affected regions. Genetic analyses
of GV span six decades, with the goal of understanding
biological mechanisms and elucidating pathways that
underlie the disease. The earliest studies attempted to
describe the mode of inheritance and genetic epide-
miology. Early genetic association studies of biological
candidate genes resulted in some successes, principally
HLA and PTPN22, but in hindsight many such reports
now seem to be false-positives. Later, genome-wide
linkage studies of multiplex GV families identified
NLRP1 and XBP1, which appear to be valid GV sus-
ceptibility genes that control key aspects of immune
regulation. Recently, the application of genome-wide
association studies to analysis of GV has produced a
rich yield of validated GV susceptibility genes that
encode components of biological pathways reaching
from immune cells to the melanocyte. These genes
and pathways provide insights into underlying patho-
genetic mechanisms and possible triggers of GV,
establish relationships to other autoimmune diseases,
and may provide clues to potential new approaches to
GV treatment and perhaps even prevention. These
results thus validate the hopes and efforts of the early
investigators who first attempted to comprehend the
genetic basis of vitiligo.
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jid.2011.321; published online 13 October 2011
INTRODUCTION
Generalized vitiligo (GV) is a complex disorder in which
acquired, progressive, multifocal loss of pigmentation of skin
and hair results from loss of melanocytes from the affected
areas (Taı¨eb and Picardo, 2009; Birlea et al., 2011b).
Although the striking phenotype of GV has been recognized
for thousands of years (Nordlund et al., 2006), its underlying
pathobiology has remained largely unknown, despite the
suggestion of numerous theories (Boissy and Spritz, 2009;
Picardo and Taı¨eb, 2010). Some of the earliest attempts to
understand the biology of GV considered its possible genetic
basis, in the hope that understanding the genetics would lead
to insights into basic pathogenetic mechanisms of disease
(Stu¨ttgen, 1950; Teindel, 1950; Lerner, 1959). Over the next
four decades, various types of genetic studies aimed to
discover genes involved in mediating GV susceptibility, with
limited success. However, recently genome-wide genetic
association studies have succeeded in identifying a veritable
cornucopia of GV susceptibility genes, encoding components
of biological networks that largely regulate elements of the
immune system and their targeting and destruction of
melanocytes.
EPIDEMIOLOGICAL STUDIES
Probably the earliest evidence relating to the genetic basis of
vitiligo was the 1855 description by Addison of a patient
with idiopathic adrenal insufficiency (now known as
Addison’s disease), GV, and pernicious anemia (Addison,
1855). Over the next century numerous case reports des-
cribed co-occurrence of GV and various other autoimmune
diseases, and in 1908 Claude and Gourgerot (1908)
suggested the likelihood of a causal connection among
autoimmune diseases that tended to occur concomitantly.
In 1926, Schmidt codified the concomitant occurrence of
Addison’s disease and autoimmune thyroid disease, in what
came to be called ‘‘Schmidt syndrome’’ (Schmidt, 1926), and
in 1980, Neufeld and Blizzard re-classified the so-called
‘‘autoimmune polyglandular syndromes’’ (APS), denoting a
rare autosomal recessive form (sometimes including GV) as
APS-1, denoting Schmidt syndrome (sometimes including
GV) as APS-2, denoting concomitant occurrence of auto-
immune thyroid disease with at least one other autoimmune
disease (again, often including GV) as APS-3, and denoting
all other combinations of autoimmune diseases as APS-4
(Neufeld and Blizzard, 1980). Although there have been a
number of subsequent attempts to refine the APS classifica-
tion, except for APS-1 (now renamed APECED; autoimmune
polyendocrinopathy, candidiasis, ectodermal dystrophy,
resulting from mutations in the AIRE gene), this system is
no longer widely used. Instead, it has become clear that
‘‘multiple autoimmune disease’’ is more complex, and that
GV is part of a more general autoimmune disease diathesis.
Indeed, the frequencies of many other autoimmune diseases,
particularly including autoimmune thyroid disease (Hashi-
moto’s thyroiditis and Graves’ disease), adult-onset type 1
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diabetes mellitus, rheumatoid arthritis, psoriasis, pernicious
anemia, Addison’s disease, and systemic lupus erythematosus
(SLE), are elevated among GV patients (Alkhateeb et al.,
2003; LaBerge et al., 2005; Sun et al., 2006). Furthermore,
the frequencies of these same autoimmune diseases are
elevated among the first-degree relatives of GV patients, even
those who do not have GV (Alkhateeb et al., 2003; LaBerge
et al., 2005). This has led to the belief that general
susceptibility to autoimmunity is a complex trait involving
various shared susceptibility genes, whereas other genes and
exposure to unknown environmental triggers determine the
occurrence of GV and other specific autoimmune diseases in
individual patients (Spritz, 2008).
In addition, genetic epidemiological studies have ad-
dressed the likely mode of inheritance of GV. Although there
had been a number of previous case reports describing the
occurrence of GV in occasional relatives, perhaps the first to
address the inheritance of GV specifically were Stu¨ttgen
(1950) and Teindel (1950), who described multigenerational
families with multiple cases of GV (‘‘multiplex families’’) and
other autoimmune diseases, concluding that autosomal
dominant inheritance seemed likely. On the basis of a
survey of 128 vitiligo patients, Lerner (1959) noted that
38% reported affected relatives, and concluded that the
‘‘disease is often transmitted as a dominant trait.’’ However,
although many subsequent patient surveys around the world
confirmed frequent clustering of vitiligo cases within families
(Mehta et al., 1973; Howitz et al., 1977; Obe, 1984; Das
et al., 1985; Bhatia et al., 1992; Majumder et al., 1993;
Kim et al., 1998; Alkhateeb et al., 2003; Sun et al., 2006), a
single-locus Mendelian pattern of inheritance was not
supported, and most favored a polygenic, multifactorial
model involving multiple genes and also environmental risk
factors, what is now termed a ‘‘complex trait’’. A major
environmental component in GV is also indicated by its
limited concordance in monozygotic twins; among 22 such
twin pairs, Alkhateeb et al. (2003) reported a concordance of
only 23%, underscoring the importance of environmental
triggers in disease pathogenesis.
CANDIDATE GENE ASSOCIATION STUDIES
The earliest analyses testing the involvement of specific
genes in the pathogenesis of GV were candidate gene
association studies, of HLA (Retornaz et al., 1976), ABO
(Kareemullah et al., 1977), and other blood groups (Wasfi
et al., 1980), and were generally negative. A large number
of ‘‘positive’’ candidate gene associations with GV have been
reported subsequently (reviewed in Birlea et al., 2011a).
However, candidate gene association studies of complex
diseases have generally proven to be highly subject to
false-positive artifacts, principally due to occult ethnic
differences between cases and controls (population stratifica-
tion) and inadequate correction for multiple testing (Hirsch-
horn et al., 2002; Freedman et al., 2004), and thus have fallen
into general disfavor. Except for HLA and PTPN22, most
candidate gene associations reported for GV have not
been confirmed by subsequent studies (reviewed in Birlea
et al., 2011a).
GENOME-WIDE LINKAGE STUDIES
Genome-wide linkage and association studies are not biased
by a priori biological hypotheses and are less subject to
methodological pitfalls than are candidate gene approaches.
Genetic linkage studies are best suited to detect relatively
rare disease susceptibility alleles with large effects, as in
multiplex families. Although genetic linkage studies are
typically carried out genome-wide, in fact, the first linkage
analysis reported for GV was a negative study, testing linkage
of a candidate gene, MITF (Tripathi et al., 1999). The first
direct genome-wide linkage study of GV, in a unique large
Caucasian kindred with apparent autosomal dominant
inheritance with incomplete penetrance, detected linkage
in chromosome 1p31.3–p32.2 (‘‘AIS1’’; Alkhateeb et al.,
2002). Subsequent DNA sequence analysis of genes in the
chromosome 1p linkage interval identified a transcriptional
regulatory variant of FOXD3, which encodes Forkhead box
D3), a key regulator of melanoblast lineage differentiation
and development (Alkhateeb et al., 2005).
Genome-wide linkage studies of numerous other Cauca-
sian multiplex GV families identified additional linkage
signals on chromosomes 7, 8, 9, 11, 13, 17, 19, and 22
(Fain et al., 2003; Spritz et al., 2004). The strongest of these
signals, on chromosome 17p13, coincided with SLEV1, a
linkage signal for systemic lupus erythematosus detected in
families that also included at least one relative with GV
(Nath et al., 2001) or other autoimmune diseases (Johansson
et al., 2004). Targeted family-based genetic association
analysis of single-nucleotide polymorphisms (SNPs) spanning
the chromosome 17p linkage interval identified the corre-
sponding gene as NALP1 (now renamed NLRP1), encoding
NACHT, LRR, and PYD domains-containing protein 1 (Jin
et al., 2007b), a key regulator of the innate immune system
that apparently functions as a sentinel for bacterial infection
in the skin (Lamkanfi and Dixit, 2009). Several studies
have subsequently confirmed association of NLRP1 with GV
(Jin et al., 2007a; Alkhateeb and Qarqaz, 2010), and also
with type 1 diabetes (Magitta et al., 2009), Addison’s
disease (Magitta et al., 2009; Zurawek et al., 2010), celiac
disease (Pontillo et al., 2011), systemic sclerosis (Dieude´
et al., 2010), and perhaps inflammatory bowel disease
(De Iudicibus et al., 2011).
Parallel genetic linkage studies of GV in Han Chinese
detected linkage signals on chromosomes 1, 4, 6, 14, and
22 (Chen et al., 2005; Liang et al., 2007). These linkage
signals generally did not correspond to those detected in
Caucasian families, suggesting that different genes might
underlie GV susceptibility in these different populations.
By candidate gene association analysis of several genes
located within the chromosome 22q12.1–12.3 linkage peak,
Ren et al. (2009) subsequently identified XBP1, encoding
transcription factor X-box binding protein 1, which activates
HLA class II gene expression, regulates plasma cell differ-
entiation, and mediates inflammatory response to endoplas-
mic reticulum stress. Additional support for involvement
of XBP1 in the pathogenesis of GV came from a subsequent
genome-wide association study (GWAS) of Caucasians
(Birlea et al., 2011a), and XBP1 has been independently
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associated with genetic risk of Crohn’s disease (Kaser et al.,
2008).
GENOME-WIDE ASSOCIATION STUDIES
Genome-wide association studies (GWAS) are best suited to
detect relatively common disease susceptibility alleles with
modest effects, as may be most relevant to typical singleton
cases of a complex disease such as GV. Of particular
importance, GWAS can adequately correct for both popula-
tion stratification and multiple testing (Hirschhorn et al.,
2002; Freedman et al., 2004), and so are currently considered
the ‘‘gold standard’’ for identifying complex trait suscepti-
bility genes.
The first GV GWAS (Birlea et al., 2010) involved a
‘‘special population’’, an isolated village with a very high
prevalence of GV located in the mountains of northwestern
Romania (Birlea et al., 2008). This analysis detected
GV association with SNPs in distal chromosome 6q27, in
the vicinity of IDDM8, a linkage and association signal for
type I diabetes mellitus and rheumatoid arthritis.
A subsequent, much larger GWAS in Caucasians
detected at least 13 different GV susceptibility loci (Table 1;
Jin et al., 2010a, b), and confirmed three others that had been
reported in previous candidate gene studies (Birlea et al.,
2011a). A parallel GV GWAS in Chinese (Quan et al.,
2010) detected two association signals, one or both of which
were among those detected in Caucasians (Table 1). In both
the Caucasian and Chinese studies, strong GV associ-
ation signals were detected in the major histocompatibility
complex (MHC) on chromosome 6p21.3. In Caucasians,
independent associations were detected in both the MHC
class I and class II gene regions. In the class I region, the
major association signal was in the vicinity of HLA-A, in
strong linkage disequilibrium with HLA-A*02. In the class II
region, the major association signal was located between
HLA–DRB1 and HLA–DQA1, in moderate linkage disequili-
brium with HLA-DRB1*04 (Jin et al., 2010a). These results
are thus consistent with previous reports of association of GV
with both HLA-A*02 (Liu et al., 2007) and HLA–DRB1*04
(Fain et al., 2006) alleles. However, in Chinese, the major
MHC association signal was in the class III gene region, with
some evidence for additional association in the class II gene
region (Quan et al., 2010).
Perhaps more important, these two large-scale GV GWASs
also detected association with a number of non-MHC loci,
almost all of which encode immunoregulatory proteins.
The Caucasian GWAS (Jin et al., 2010a, b) detected associa-
tions with SNPs in at least 10 non-MHC loci: TYR
(tyrosinase), PTPN22 (lymphoid-specific protein tyrosine
phosphatase nonreceptor type 22), RERE (arginine-glutamic
acid dipeptide (RE) repeats protein; atrophin-like protein 1),
FOXP1 (forkhead box P1), LPP (LIM domain-containing
preferred translocation partner in lipoma), IL2RA (IL-2
receptor alpha chain), GZMB (granzyme B), UBASH3A
(ubiquitin-associated and SH3 domain-containing A),
C1QTNF6 (C1q and tumor necrosis factor-related protein
6), and CCR6 (C-C chemokine receptor type 6). This last gene
is located very close to the 6q27 association signal detected
in the Romanian village (Birlea et al., 2010), and was the only
non-MHC locus detected in the Chinese GWAS (Quan et al.,
2010). The Caucasian GWAS also provided evidence of
association of GV with additional loci previously suggested
as candidate genes for GV: XBP1 (see above), FOXP3
(forkhead box P3), TSLP (thymic stromal lymphoprotein),
and CTLA4 (cytotoxic T-lymphocyte antigen 4), although as
in previous studies association of GV with CTLA4 appeared
to perhaps reflect primary association with other concomitant
autoimmune diseases in the GV cases, rather than with GV
itself (Birlea et al., 2011a).
Among the most illuminating associations with GV are
those of MHC class I and TYR, which together highlight
one of the pathways by which the immune system ‘‘sees’’
and thus targets melanocytes. The MHC class I association in
Caucasians with GV is with SNP rs12206499, which tags
HLA-A*02 (predominantly HLA-A*02:01), while the TYR
association with GV is with the major (R; Arg) allele of
the R402Q polymorphism (SNP rs1126809) that is relatively
common among Caucasians (minor allele frequency
0.22–0.40), but is rare in other populations (Tripathi et al.,
1991). In contrast, the minor (Q; Gln) allele of the
TYR R402Q polymorphism is associated with susceptibility
to malignant melanoma (Gudbjartsson et al., 2008; Bishop
et al., 2009), while HLA-A*02 is associated with relatively
favorable response to melanoma immunotherapy (Mitchell
et al., 1992). Tyrosinase is a major GV autoantigen presented
to the immune system on the surface of melanocytes
and melanoma cells by HLA class I molecules, principally
HLA-A*02. One of the important epitopes presented by HLA-
A*02 is a modified tyrosinase nonapeptide, YMDGTMSQV
(Skipper et al., 1996). However, the variant 402Q form of
tyrosinase is hypoglycosylated (Toyofuku et al., 2001), which
in turn would prevent the modification that is essential for its
antigenic presentation by HLA-A*02. As the result, tyrosi-
nase-402R likely makes a quantitatively greater contribution
than tyrosinase-402Q to presentation of antigenic tyrosinase
by HLA-A*02. Together, these findings indicate an apparent
inverse relationship between genetic susceptibility to GV and
genetic susceptibility to malignant melanoma as mediated by
TYR and HLA-A*02 (Jin et al., 2010a), suggesting that
GV may represent a dysregulated mechanism of immune
surveillance against malignant melanoma, with TYR
R402Q modulating immune recognition of melanocytes by
modulating availability of tyrosinase peptide for presentation
by HLA-A*02 (Spritz, 2010).
In addition to primary searches for genes that influence
disease susceptibility per se, genome-wide approaches can
also be used to identify genes that influence the natural
history of disease. Such an approach has recently been taken
to identify a locus that contributes to GV age of onset
(Jin et al., 2011). These authors’ reanalyzed their previous
GV GWAS data set, considering only the affected individuals,
in whom GV age of onset was assessed as a quantitative trait.
This analysis identified a major GV age of onset locus in the
MHC class II region, apparently reflecting the same locus
that was associated with GV susceptibility (Jin et al., 2010a),
while none of the other loci that had been associated with
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GV susceptibility per se were associated with age of onset.
These results indicate that some loci likely mediate GV
susceptibility per se, whereas other loci, particularly variation
in the MHC class II region, might mediate response to
environmental triggers encountered over the course of life,
thereby influencing age of disease onset.
Table 1. Loci with confirmed involvement in GV susceptibility on the basis of genome-wide studies1
Chromosome Gene Protein Function Causal variant
Other autoimmune
disease associations
1p36.23 RERE Atrophin-like protein 1 Regulates apoptosis
1p13.2 PTPN22 Lymphoid-specific protein
tyrosine phosphatase
nonreceptor type 22
Regulates TCR signaling R620W Type 1 diabetes, SLE, Graves’
disease, rheumatoid arthritis,
Addison’s disease, psoriasis,
inflammatory bowel disease
2q33.2 CTLA4 2 Cytotoxic T-lymphocyte
antigen 4
Inhibits T cells Type 1 diabetes, Graves’
disease, Hashimoto’s
thyroiditis, inflammatory
bowel disease, SLE
3p13 FOXP1 Forkhead box P1 Regulates lymphoid cell
development
3q28 LPP LIM domain-containing
preferred translocation
partner in lipoma
Unknown Celiac disease, rheumatoid
arthritis
5q22.1 TSLP Thymic stromal
lymphoprotein
Regulates T-cell and dendritic
cell maturation
6p21.3 MHC class I (HLA-A) HLA-a chain Presents peptide antigens *02:01 Many
MHC class II3 Unknown Many
MHC class III Unknown Many
6q27 CCR6 C-C chemokine receptor
type 6
Regulates B-cell differentiation,
function of dendritic and Th17
cells
Inflammatory bowel disease,
rheumatoid arthritis, Graves’
disease
10p15.1 IL2RA IL-2 receptor a-chain Regulates lymphocyte response
to bacteria via IL2
Type 1 diabetes, Graves’
disease, multiple sclerosis,
rheumatoid arthritis, SLE
11q14.3 TYR Tyrosinase Key enzyme of melanin
biosynthesis
R402Q
14q12 GZMB Granzyme B Mediates target cell apoptosis by
cytotoxic T cells and natural
killer cells, activation-induced
cell death of effector Th2 cells
17p13.2 NLRP1 NACHT, LRR, and PYD
domains-containing
protein 1
Type 1 diabetes, Addison’s
disease, celiac disease,
systemic sclerosis
21q22.3 UBASH3A Ubiquitin-associated and
SH3 domain-containing A
Regulates TCR signaling Type 1 diabetes
22q12.1 XBP1 X-box binding protein 1 Regulates expression of HLA
class II genes, IL6, B-cell and
plasma cell differentiation
Crohn’s disease
22q13.1 C1QTNF6 C1q and tumor necrosis
factor-related protein 6
Unknown Type 1 diabetes, rheumatoid
arthritis
Xp11.23 FOXP3 Forkhead box P3 Regulates regulatory T cells Defective gene in immuno-
dysregulation polyendo-
crinopathy enteropathy
X-linked syndrome
Abbreviations: GV, generalized vitiligo; MHC, major histocompatibility complex; SLE, systemic lupus erythematosus.
1Adapted from Spritz (2011).
2Numerous studies have indicated that CTLA4 is only associated with GV in patients who also have other autoimmune diseases, suggesting that apparent
association of CLTA4 with GV is secondary to epidemiological association with these other diseases.
3The MHC class II region is associated with both GV susceptibility and age of onset.
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PERSPECTIVE
For GV as for many other complex diseases, application of
genome-wide approaches, particularly GWAS, has resulted
in rapid progress in identifying true disease susceptibility
genes, while most genes suggested as a priori biologically
based candidates have remained unconfirmed. Accordingly,
for GV as for many other diseases, we have entered a new
era of understanding the true underlying pathobiology,
which in the case of GV appears to be predominantly
autoimmune. Furthermore, many of the genes that are
genetically associated with GV are also genetically asso-
ciated with some of the other autoimmune diseases with
which GV is epidemiologically associated, confirming the
longstanding hypothesis that these epidemiological associ-
ations reflect underlying shared causal elements (Claude and
Gourgerot, 1908).
The studies carried out so far have identified a plethora
of new biological pathways that constitute potential targets
for therapeutic intervention and perhaps even disease
prevention. However, these findings only scratch the surface,
accounting for a relatively small portion of total disease
risk. Larger genome-wide studies can be expected to identify
even more GV susceptibility genes and thus shed even more
light on the nature of the disease, and perhaps even provide
clues to environmental triggers. Moreover, for only a few
of the GV susceptibility genes found thus far have the
corresponding underlying causal variants been identified; this
will require extensive DNA sequencing of large numbers
of GV patients, careful bioinformatics analysis, and targeted
functional studies to assess the effects of specific variants,
both individually and in combination. Nevertheless, the
way forward is now clear, with many doors opening to
new understanding and new opportunities for treating
patients with GV.
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